Title:
CDK9 AS MODIFIER OF THE IGF PATHWAY AND METHODS OF USE
Document Type and Number:
WIPO Patent Application WO2006009933
Kind Code:
A3
Abstract:
Human CDK9 genes are identified as modulators of the IGF pathway, and thus are therapeutic targets for disorders associated with defective IGF function. Methods for identifying modulators of IGF, comprising screening for agents that modulate the activity of CDK9 are provided.
Inventors:
MAXWELL MARK E (US)
OLLMANN MICHAEL MARTIN (US)
HEUER TIMOTHY S (US)
BJERKE LYNN MARGARET (GB)
OLLMANN MICHAEL MARTIN (US)
HEUER TIMOTHY S (US)
BJERKE LYNN MARGARET (GB)
Application Number:
PCT/US2005/021630
Publication Date:
November 16, 2006
Filing Date:
June 20, 2005
Export Citation:
Assignee:
EXELIXIS INC (US)
MAXWELL MARK E (US)
OLLMANN MICHAEL MARTIN (US)
HEUER TIMOTHY S (US)
BJERKE LYNN MARGARET (GB)
MAXWELL MARK E (US)
OLLMANN MICHAEL MARTIN (US)
HEUER TIMOTHY S (US)
BJERKE LYNN MARGARET (GB)
International Classes:
G01N33/53; C07H21/04; C12N9/12; C12Q1/48
Foreign References:
| US20040082613A1 | 2004-04-29 |
Other References:
YU H. ET AL.: "Plasma Levels of Insulin-like Growth actor-1 and Lung Cancer Risk: a Case-Control Analysis", JOURNAL OF THE NATIONAL CANCER INSTITUTE, vol. 91, no. 2, 20 January 1999 (1999-01-20), pages 151 - 156, XP003002158
STAMBOLIC ET AL.: "Negative Regulation of PKB/Akt-Dependent Cell Survival by the Tumor Suppressor PTEN", CELL, vol. 95, no. 1, 2 October 1998 (1998-10-02), pages 29 - 39, XP002984475
See also references of EP 1759206A4
STAMBOLIC ET AL.: "Negative Regulation of PKB/Akt-Dependent Cell Survival by the Tumor Suppressor PTEN", CELL, vol. 95, no. 1, 2 October 1998 (1998-10-02), pages 29 - 39, XP002984475
See also references of EP 1759206A4
Download PDF:
Previous Patent: CONSOLIDATED ETHERNET OPTICAL NETWORK AND APPARATUS
Next Patent: NOVEL ESTERS AS USEFUL BROAD SPECTRUM HERBICIDAL COMPOUNDS
Next Patent: NOVEL ESTERS AS USEFUL BROAD SPECTRUM HERBICIDAL COMPOUNDS